drugset / Trial / NCT00576667

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

NCT00576667

Phase 3 Terminated 165 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effect of Rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH).

Timeline

Start
2008-01
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimonabant Small molecule 20 mg Oral

Indications